Holen Sie sich die Stockscreener-App
0.958
8.75%
0.0674
Schlusskurs vom Vortag:
$0.8906
Offen:
$0.9
24-Stunden-Volumen:
758.64K
Relative Volume:
0.35
Marktkapitalisierung:
$108.94M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.3685
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
-6.88%
1M Leistung:
-17.92%
6M Leistung:
-25.50%
1J Leistung:
-55.37%
1-Tages-Spanne:
$0.8955
$0.9994
1-Wochen-Bereich:
$0.874
$1.18
52-Wochen-Spanne:
$0.6603
$2.64
Coherus Biosciences Inc Stock (CHRS) Company Profile
Firmenname
Coherus Biosciences Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
0.958 | 108.94M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.49 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.81 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.80 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten
Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - Citeline News & Insights
Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus BioSciences (NASDAQ:CHRS) Receives “Buy” Rating from HC Wainwright - Defense World
Coherus BioSciences’ Earnings Call: Growth and Challenges - TipRanks
Coherus Biosciences: Strategic Divestment and Pipeline Focus Justify Buy Rating - TipRanks
Coherus stock rating upgraded on Loqtorzi sales growth By Investing.com - Investing.com Australia
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Coherus BioSciences Q4 2024 sees revenue beat By Investing.com - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Transition - GuruFocus.com
Coherus BioSciences earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Earnings call transcript: Coherus BioSciences Q4 2024 sees revenue beat - Investing.com
Coherus BioSciences: Q4 Earnings Snapshot - mySA
Coherus BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coherus Biosciences, Inc. Q4 Loss Narrows - Nasdaq
Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines -March 10, 2025 at 04:47 pm EDT - Marketscreener.com
Coherus BioSciences Q4 revenue tops estimates, shares edge higher By Investing.com - Investing.com South Africa
Coherus BioSciences Q4 revenue tops estimates, shares edge higher - Investing.com India
Coherus BioSciences: Q4 Earnings Snapshot -March 10, 2025 at 04:33 pm EDT - Marketscreener.com
COHERUS BIOSCIENCES Earnings Results: $CHRS Reports Quarterly Earnings - Nasdaq
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides ... - Bluefield Daily Telegraph
Coherus Biotech Revenue Hits $267M, Plans Major Oncology Pivot - StockTitan
Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’ - News & Insights
What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earni - GuruFocus.com
What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings - Yahoo Finance
New York State Common Retirement Fund Sells 90,585 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc. to Host Earnings Call - ACCESS Newswire
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
Coherus BioSciences (CHRS) Expected to Announce Earnings on Monday - Defense World
Institutional owners may consider drastic measures as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent US$17m drop adds to long-term losses - Simply Wall St
Coherus BioSciences announces supplemental disclosures By Investing.com - Investing.com South Africa
Coherus BioSciences announces supplemental disclosures - Investing.com
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 - GlobeNewswire
CHRSCoherus Bioscien Latest Stock News & Market Updates - StockTitan
Coherus BioSciences to Release Q4 and Full Year 2024 Financial Results on March 10, 2025 - Nasdaq
When Will Coherus Reveal Its 2024 Performance? Key Date for Biotech Investors - StockTitan
Investor Network: Coherus BioSciences, Inc. to Host Earnings Call - ACCESS Newswire
With 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns - Yahoo Canada Finance
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference - GlobeNewswire
Can Coherus Management Reveal New Strategic Plans at TD Cowen Conference? - StockTitan
Coherus Management To Participate At The 45th Annual TD Cowen Health Care Conference - Barchart
Psoriasis Biosimilars Market Top Players- Merck KGaA, Coherus - openPR
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results - br.ADVFN.com
Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):